+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Brain Cancer Drugs Market by Drug Class, Tumor Type, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Brain Cancer Drugs Market by Drug Class, Tumor Type, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Brain Cancer Drugs Market by Drug Class, Tumor Type, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011104
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Brain Cancer Drugs Market grew from USD 2.18 billion in 2024 to USD 2.34 billion in 2025. It is expected to continue growing at a CAGR of 7.45%, reaching USD 3.36 billion by 2030.

Unveiling the Future of Brain Cancer Therapeutics

The global landscape for brain cancer therapies is undergoing a dynamic transformation driven by scientific breakthroughs, shifting regulatory frameworks, and evolving patient needs. As novel treatment modalities emerge, stakeholders across healthcare and life sciences seek clear insights into the forces shaping this critical market segment. This executive summary distills complex data and rigorous analysis into an accessible narrative that informs strategic planning, investment decisions, and research priorities.

By exploring the latest advances in therapeutic modalities, examining the impact of policy changes, and revealing granular segmentation trends, this report lays the foundation for a robust understanding of where the market stands today and where it is headed. It highlights the competitive nuances that distinguish leading developers, the regional dynamics that influence adoption rates, and the technological drivers fueling next-generation drug pipelines.

Whether you are an executive charting a strategic roadmap, an investor evaluating growth opportunities, or a researcher seeking a comprehensive overview, this introduction sets the stage for a deeper dive into the forces reshaping the brain cancer drugs sector. It underscores the importance of timely intelligence and actionable recommendations in navigating a market characterized by rapid innovation and complex regulatory environments.

Pioneering Advances Redefining Treatment Paradigms

In recent years, the brain cancer drugs market has witnessed transformative shifts that are redefining treatment paradigms and patient outcomes. A surge in precision medicine has enabled therapies tailored to unique molecular profiles, while advances in immunotherapy have unlocked the potential for durable responses in previously refractory tumor types. Concurrently, digital health platforms now facilitate real-time monitoring of neurological status and drug efficacy, enhancing the patient journey from diagnosis through survivorship.

Technological breakthroughs in drug delivery systems, such as nanocarriers and convection-enhanced delivery, are overcoming historical barriers to penetration of the blood-brain barrier. These innovations are complemented by progress in combination regimens that synergize targeted therapies with checkpoint inhibitors, offering hope for sustained remission. Meanwhile, regulatory bodies have introduced adaptive pathways to expedite the review of breakthrough designations, accelerating the time to market for promising candidates.

Collectively, these seminal shifts are fostering a more collaborative ecosystem among academia, biopharma, and technology firms. As stakeholders converge around shared goals of personalization, precision, and patient-centricity, the industry is poised to deliver a new era of brain cancer care that expands therapeutic options and improves long-term outcomes.

Navigating Trade Dynamics and Supply Chain Resilience

The implementation of cumulative United States tariffs in 2025 has exerted a discernible impact on the global supply chain for brain cancer therapeutics. Manufacturers have confronted rising input costs for key active pharmaceutical ingredients sourced from international partners, prompting a reevaluation of procurement strategies and a shift toward regional manufacturing hubs. These adaptations, in turn, have influenced pricing structures and reimbursement negotiations across major markets.

Compounding these challenges, logistics bottlenecks associated with higher duties have led to sporadic delays in delivery schedules, compelling distributors and healthcare providers to increase safety stock levels to ensure uninterrupted patient access. In response, some innovators have pursued vertical integration to retain greater control over critical components of the value chain, from raw materials to finished dosage forms.

Despite these headwinds, the tariff environment has catalyzed new strategic alliances between domestic contract development and manufacturing organizations and specialized biotech firms. By localizing essential operations, companies are mitigating exposure to further trade disruptions and preserving agility in clinical supply. As a result, the market is witnessing a recalibration of global trade flows that balances cost considerations with the imperative of timely patient care.

Illuminating Key Market Segments with Precision

The brain cancer drugs market is dissected through multiple lenses to reveal nuanced growth pockets. When viewed by therapeutic class, chemotherapy remains a mainstay of care, with alkylating agents continuing to anchor treatment regimens alongside evolving antimetabolites and plant alkaloids. Immunotherapy has emerged as a high-growth segment, driven by the promise of cancer vaccines, advanced CAR-T platforms, and novel checkpoint inhibitors. Supportive therapies play a critical role in enhancing quality of life, particularly through anti-emetic protocols and targeted growth factor support. Targeted therapy is rapidly expanding, with monoclonal antibodies and tyrosine kinase inhibitors offering new lines of attack against tumor-specific molecular aberrations.

Tumor type segmentation highlights distinct clinical and commercial considerations. Glioblastoma, with its aggressive nature, commands significant R&D investment, while rarer subtypes such as astrocytoma and oligodendroglioma benefit from precision diagnostics that inform tailored regimens. Medulloblastoma and ependymoma, prevalent in pediatric populations, underscore the importance of age-adapted dosing and long-term survivorship strategies.

In terms of administration, intravenous delivery continues to dominate in hospital settings, though oral formulations and intrathecal approaches are gaining traction for their convenience and targeted CNS penetration. On the user end, hospitals and specialized clinics remain pivotal centers for complex therapeutic protocols, even as home healthcare models grow to support maintenance phases. Distribution channels balance immediacy and accessibility, with hospital pharmacies serving as primary dispensaries and retail and online pharmacies offering supplemental pathways for patient convenience.

Decoding Regional Variations that Drive Growth

Regional dynamics in the brain cancer drugs market reveal differentiated trajectories shaped by healthcare infrastructure and policy environments. In the Americas, established reimbursement frameworks and robust clinical trial networks underpin rapid adoption of innovative therapies, though cost containment pressures continue to drive negotiations between payers and manufacturers. Europe, the Middle East and Africa present a heterogeneous landscape: Western Europe experiences consistent uptake of novel modalities, while emerging markets in the Middle East and North Africa prioritize capacity building and access programs. Simultaneously, Asia-Pacific is characterized by accelerating regulatory reform and expanding domestic manufacturing capabilities, particularly in East Asia, where government incentives are fueling local biotech innovation.

Despite these regional contrasts, a unifying trend is the expansion of patient access initiatives and public-private collaborations that aim to bridge gaps in care. Cross-border partnerships and harmonized clinical study protocols are becoming increasingly common, accelerating the diffusion of best practices and emerging standards of care. As a result, companies that tailor their market entry strategies to the specific regulatory and economic nuances of each region will be best positioned to capture growth opportunities and deliver sustainable patient impact.

Competitive Strategies Powering Industry Leadership

Leading organizations in the brain cancer drugs arena are forging transdisciplinary collaborations to strengthen their pipelines and market positions. Established pharmaceutical firms are augmenting their small-molecule portfolios with biologics through in-licensing agreements and joint ventures, while nimble biotechnology start-ups are leveraging cutting-edge platforms such as gene editing and synthetic biology. Clinical development strategies increasingly incorporate adaptive trial designs and biomarker-driven cohorts, enabling accelerated pathways for high-potential candidates.

Investment in proprietary delivery technologies has emerged as a competitive differentiator, with several companies securing patent protection for next-generation nanocarrier systems and convection-enhanced infusion devices. Strategic acquisitions have also reshaped the competitive landscape, as major players integrate complementary assets to secure broader therapeutic coverage. Furthermore, partnerships with academic centers and contract research organizations are underpinning robust translational platforms that translate laboratory discoveries into clinical milestones more efficiently.

Companies that balance deep scientific expertise with agile commercialization capabilities are gaining traction, particularly in markets that demand personalized treatment regimens and real-world evidence to support value-based pricing. As intellectual property milestones approach expiration, incumbents and challengers alike are reinforcing their pipelines through a combination of organic R&D and targeted M&A activity.

Strategic Imperatives for Market Leadership

To thrive amidst ongoing innovation and market complexity, industry leaders should prioritize investment in precision oncology initiatives that harness molecular diagnostics and digital biomarkers. By integrating real-world data streams into development programs, organizations can refine patient selection criteria, optimize dosing schedules, and demonstrate compelling health economic value to payers.

Supply chain diversification is equally critical. Establishing regional manufacturing footprints and forging strategic partnerships with contract development and manufacturing organizations will mitigate risks associated with geopolitical volatility. Leaders should also cultivate agile procurement models that allow rapid scale-up or scale-down in response to evolving demand patterns.

Collaboration remains a cornerstone of progress: alliances with academic research hubs, patient advocacy groups, and health technology platforms can accelerate the translation of laboratory breakthroughs into clinical practice. Finally, embedding patient-centric design principles into every stage of development-from trial protocols to post-launch support-will enhance adoption rates and foster long-term loyalty among care providers and patients alike.

Rigorous Research Foundations Ensuring Accuracy

This research draws on a dual-pronged methodology that combines extensive secondary research with targeted primary data collection. Secondary sources include peer-reviewed journals, clinical trial registries, patent filings, regulatory agency reports, and industry whitepapers. These materials provided a comprehensive foundation of historical trends, scientific advances, and market dynamics.

Primary research involved in-depth interviews with key opinion leaders, industry executives, regulatory experts, and healthcare practitioners. These conversations offered qualitative insights into emerging technologies, reimbursement environments, and patient access challenges. Quantitative data was validated through triangulation across multiple databases and proprietary intelligence platforms, ensuring consistency and reliability.

Analytical frameworks such as SWOT and Porter’s Five Forces were applied to assess competitive intensity and market attractiveness. Segmentation analyses were performed using structured market modeling techniques, and regional outlooks were cross-verified with local stakeholders to capture country-level nuances. Rigorous quality assurance protocols, including peer reviews and editorial checks, were employed throughout the research process to uphold methodological integrity.

Synthesis of Insights Guiding Future Directions

In summary, the brain cancer drugs market stands at a pivotal juncture where technological innovation converges with evolving policy landscapes and shifting patient expectations. Precision medicine and immunotherapy are expanding the frontiers of treatment, while regulatory adaptations and supply chain realignments shape commercial realities. Granular segmentation and regional insights elucidate diverse opportunities, and competitive intelligence highlights the strategic maneuvers of leading organizations.

By synthesizing these dimensions, this executive summary equips stakeholders with the critical intelligence needed to navigate uncertainty, capitalize on emerging trends, and deliver transformative therapies to patients. In a domain where scientific complexity and clinical urgency intersect, informed decision-making is paramount. The depth and breadth of analysis presented here illuminate the path forward for sustainable growth and meaningful patient impact.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Chemotherapy
      • Alkylating Agents
      • Antimetabolites
      • Plant Alkaloids
    • Immunotherapy
      • Cancer Vaccines
      • CAR-T Therapy
      • Checkpoint Inhibitors
    • Supportive Therapy
      • Anti-Emetics
      • Growth Factors
    • Targeted Therapy
      • Monoclonal Antibodies
      • Tyrosine Kinase Inhibitors
  • Tumor Type
    • Astrocytoma
    • Ependymoma
    • Glioblastoma
    • Medulloblastoma
    • Oligodendroglioma
  • Route Of Administration
    • Intrathecal
    • Intravenous
    • Oral
  • End User
    • Clinics
    • Home Healthcare
    • Hospitals
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • Bayer Aktiengesellschaft
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd
  • Amgen Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Brain Cancer Drugs Market, by Drug Class
8.1. Introduction
8.2. Chemotherapy
8.2.1. Alkylating Agents
8.2.2. Antimetabolites
8.2.3. Plant Alkaloids
8.3. Immunotherapy
8.3.1. Cancer Vaccines
8.3.2. CAR-T Therapy
8.3.3. Checkpoint Inhibitors
8.4. Supportive Therapy
8.4.1. Anti-Emetics
8.4.2. Growth Factors
8.5. Targeted Therapy
8.5.1. Monoclonal Antibodies
8.5.2. Tyrosine Kinase Inhibitors
9. Brain Cancer Drugs Market, by Tumor Type
9.1. Introduction
9.2. Astrocytoma
9.3. Ependymoma
9.4. Glioblastoma
9.5. Medulloblastoma
9.6. Oligodendroglioma
10. Brain Cancer Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Intrathecal
10.3. Intravenous
10.4. Oral
11. Brain Cancer Drugs Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Healthcare
11.4. Hospitals
12. Brain Cancer Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas Brain Cancer Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Brain Cancer Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Brain Cancer Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. Merck & Co., Inc.
16.3.3. Bristol-Myers Squibb Company
16.3.4. Novartis AG
16.3.5. Pfizer Inc.
16.3.6. Johnson & Johnson
16.3.7. Bayer Aktiengesellschaft
16.3.8. AbbVie Inc.
16.3.9. Teva Pharmaceutical Industries Ltd
16.3.10. Amgen Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BRAIN CANCER DRUGS MARKET MULTI-CURRENCY
FIGURE 2. BRAIN CANCER DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. BRAIN CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BRAIN CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY EPENDYMOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 63. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 65. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 66. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 67. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 68. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 69. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 74. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 75. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 76. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 77. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 78. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 120. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 121. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 122. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 123. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 124. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 129. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 130. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 131. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 132. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 133. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 146. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 147. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 148. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 149. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 150. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 151. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 155. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 156. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 157. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 158. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 159. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 160. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 191. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 192. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 193. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 194. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 195. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 196. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 210. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 211. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 212. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 213. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 214. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 218. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 219. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 220. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 221. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 222. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 223. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 245. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 246. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 247. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 248. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 249. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 250. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 254. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 255. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 256. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 257. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 258. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 259. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 272. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 273. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 274. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 275. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 276. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 277. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 282. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 283. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 284. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 285. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 286. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 308. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 309. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 310. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 311. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 312. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 313. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 314. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 318. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 319. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 320. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 321. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 322. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 323. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 326. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 327. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 328. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 329. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 330. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 331. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 332. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 333. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 334. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 337. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 338. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 339. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 340. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 341. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 342. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZ

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Brain Cancer Drugs market report include:
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • Bayer Aktiengesellschaft
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd
  • Amgen Inc.

Table Information

Report AttributeDetails
No. of Pages186
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.34 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.36 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Brain & Spinal Cord Cancer Market by Cancer Type, Treatment Type, Patient Age Group, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Brain & Spinal Cord Cancer Market by Cancer Type, Treatment Type, Patient Age Group, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global
From
Glioma - Pipeline Insight, 2025 - Product Image

Glioma - Pipeline Insight, 2025

  • Clinical Trials
  • 450 Pages
  • Global
From
Brain Metastases- Pipeline Insight, 2025 - Product Image

Brain Metastases- Pipeline Insight, 2025

  • Clinical Trials
  • 220 Pages
  • Global
From
Brain Tumor Therapeutics Market by Therapeutic Approach, Product Type, Tumor Type, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Brain Tumor Therapeutics Market by Therapeutic Approach, Product Type, Tumor Type, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Glioblastoma Multiforme (GBM) Treatment Market Report 2025 - Product Image

Glioblastoma Multiforme (GBM) Treatment Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Brain Cancer Drugs Market

The Brain Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat brain cancer. Brain cancer is a type of cancer that affects the cells of the brain and can be caused by a variety of factors, including genetics, environmental exposure, and lifestyle. Brain cancer drugs are used to treat the symptoms of brain cancer, such as headaches, seizures, and nausea, as well as to slow the progression of the disease. Brain cancer drugs are typically divided into two categories: chemotherapy and targeted therapy. Chemotherapy drugs are used to kill cancer cells, while targeted therapy drugs are designed to target specific cancer cells and stop them from growing. Both types of drugs are used in combination to treat brain cancer. Some of the major companies in the Brain Cancer Drugs market include Bristol-Myers Squibb, Merck, Pfizer, Novartis, and Roche. These companies are involved in the development and sale of drugs used to treat brain cancer, as well as in the research and development of new treatments. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.